Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03225963 |
Recruitment Status : Unknown
Verified July 2017 by Taichung Veterans General Hospital.
Recruitment status was: Recruiting
First Posted : July 21, 2017
Last Update Posted : July 24, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Glioblastoma Multiforme Angiogenesis | Radiation: Chemoradiation with temozolomide |
Study Type : | Observational |
Estimated Enrollment : | 60 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents. |
Actual Study Start Date : | August 1, 2015 |
Estimated Primary Completion Date : | July 31, 2018 |
Estimated Study Completion Date : | July 31, 2018 |

- Response of bevacizumab therapy. [ Time Frame: 3 months after bevacizumab therapy ]Base on the image after bevacizumab therapy (after recurrence)
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Age older than 20 year old.
- Glioblastoma patients who will receive chemoradiation treatment.
Exclusion Criteria:
- None

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03225963
Contact: Weir Chiang You, M.D. Ph.D. | 886-4-23592525 ext 5602 | bigjohnyou@vghtc.gov.tw | |
Contact: Hui Lin Yeh, M.D. | 886-4-23592525 ext 5621 | yehl@vghtc.gov.tw |
Taiwan | |
Taichung Veterans General Hospital | Recruiting |
Taichung, Taiwan, 407 | |
Contact: Weir Chiang You, M.D. PhD 886-4-23592525 ext 5602 bigjohnyou@vghtc.gov.tw |
Study Chair: | Weir Chiang You, M.D. Ph.D. | The Institutional Review Board of Taichung Veterans General Hospital |
Responsible Party: | Taichung Veterans General Hospital |
ClinicalTrials.gov Identifier: | NCT03225963 |
Other Study ID Numbers: |
CE15180B |
First Posted: | July 21, 2017 Key Record Dates |
Last Update Posted: | July 24, 2017 |
Last Verified: | July 2017 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Glioblastoma Bevacizumab |
Glioblastoma Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Temozolomide Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |